Mark Carlson, MD
Internal Medicine · Sioux City, IANPI 1609837368
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $133,082 of the $173,868 with a category attached, or 76.5%. Amgen accounts for 95.2% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2021 at $67,683 and has fallen 98.8% since, to $821 in 2025. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 643 payments — averaging $270.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$166K
- AbbVie$2K
- AstraZeneca$1K
- Novo Nordisk$536
- Bayer$499
- Esperion Therapeutics, Inc.$499
- plus $4K from 35 others
What the payments were for
- Consulting fees$1,8001%
- Speaking & faculty fees$133,08277%
- Travel & lodging$29,47517%
- Food & beverage$9,4105%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$81,885
- Otezla$81,478
- LINZESS$1,400
- FARXIGA$137
- TRELEGY ELLIPTA$123
- Veozah$118
- QULIPTA$116
- NURTEC ODT$116
How this compares
$173,868 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $67,494 |
| FarxigaDapagliflozin Propanediol | 66 | $56,577 |
| MounjaroTirzepatide | 50 | $52,579 |
| EliquisApixaban | 50 | $43,705 |
| JardianceEmpagliflozin | 42 | $43,163 |
| Repatha SureclickEvolocumab | 46 | $28,702 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $27,191 |
| MyrbetriqMirabegron | 41 | $25,111 |
| EntrestoSacubitril/Valsartan | 16 | $17,429 |
| VascepaIcosapent Ethyl | 23 | $14,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,010 |
| TrulicityDulaglutide | 12 | $13,022 |
| Praluent PenAlirocumab | 21 | $10,354 |
| TradjentaLinagliptin | 16 | $10,129 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $9,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,179 | $83,768103 claims |
| Novo NordiskOzempic | $536 | $67,49452 claims |
| Lilly USA, LLCMounjaro, Trulicity | $165 | $65,60262 claims |
| Boehringer IngelheimJardiance, Tradjenta | $307 | $53,29158 claims |
| PfizerEliquis | $385 | $43,70550 claims |
| Astellas Pharma US IncMyrbetriq | $255 | $25,11141 claims |
| GSKTrelegy Ellipta, Arexvy | $311 | $19,79839 claims |
| NovartisEntresto | $182 | $17,42916 claims |
| Esperion Therapeutics, Inc.Nexlizet | $499 | $9,54412 claims |
| AbbVieLinzess, Synthroid | $1,623 | $9,38729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Sioux City
- David DanielsSioux City$2K
- Mark JohnsonMason City$223K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
- Ali SaeedCedar Rapids$17K
- Lazaro RabangUrbandale$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.